Tag: Gallbladder disease

Based on post-marketing surveillance, thousands of adverse event reports linked to Ozempic have been filed with the FDA, detailing severe digestive problems. Understanding what gastrointestinal disease is caused by Ozempic is now a critical concern for both patients and healthcare providers.

Serious adverse events from medications are a significant health concern, making it critical to understand who should not take fibrates before starting treatment. These cholesterol-lowering drugs have specific contraindications and drug interactions that must be carefully considered for patient safety.

For patients considering a non-surgical option, dissolving gallstones with ursodiol is a gradual process requiring months, or sometimes up to two years, of continuous therapy. Success is not guaranteed for everyone, but for carefully selected patients, it can be an effective alternative to surgery.

Recent studies have highlighted a potential link between the use of semaglutide (the active ingredient in Ozempic and Wegovy) and an increased risk of several serious health conditions [1.5.1]. So, what diseases can semaglutide cause? Potential risks include pancreatitis, gallbladder disease, and thyroid tumors [1.3.2].

Fenofibrate is a fibrate-class medication prescribed to lower high triglycerides, but it is strictly contraindicated in individuals with severe kidney or active liver disease. Understanding who should avoid fenofibrate is crucial for patient safety and effective treatment.